Evidence map›Paper›PMID 34853131›Full record

ArticleSaudi medical journal2021

Impact of COVID-19 on cancer management in military hospitals of Saudi Arabia.

Omar Al Zahrani, Ismail Ghorbel, Osama Mukhtar, Muneera Almajed, Hoda M Abdelazim, Muhammad N Hasan, Ahmad Mostafa, Aisha A Al Harbi, Ali Bajouda

Open access · diamondAbstract readMulticenter Study
In one paragraph

Article in Saudi medical journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Omar Al ZahraniFrom the Department of Oncology, (Al Zahrani, Ghorbel, Mukhtar), King Salman Armed Forces Hospital, Tabuk; from the Department of Oncology, (Almajed, Abdelazim), Prince Sultan Military Medical City, Riyadh; from the Department of Oncology, (Hasan), Al Hada Armed Forces Hospital, Taif; and from the Department of Oncology, (Al Harbi, Ali Bajouda), King Fahad Armed Forces Hospital, Jeddah, Kingdom of Saudi Arabia.
Ismail GhorbelFrom the Department of Oncology, (Al Zahrani, Ghorbel, Mukhtar), King Salman Armed Forces Hospital, Tabuk; from the Department of Oncology, (Almajed, Abdelazim), Prince Sultan Military Medical City, Riyadh; from the Department of Oncology, (Hasan), Al Hada Armed Forces Hospital, Taif; and from the Department of Oncology, (Al Harbi, Ali Bajouda), King Fahad Armed Forces Hospital, Jeddah, Kingdom of Saudi Arabia.
Osama MukhtarFrom the Department of Oncology, (Al Zahrani, Ghorbel, Mukhtar), King Salman Armed Forces Hospital, Tabuk; from the Department of Oncology, (Almajed, Abdelazim), Prince Sultan Military Medical City, Riyadh; from the Department of Oncology, (Hasan), Al Hada Armed Forces Hospital, Taif; and from the Department of Oncology, (Al Harbi, Ali Bajouda), King Fahad Armed Forces Hospital, Jeddah, Kingdom of Saudi Arabia.
Muneera AlmajedFrom the Department of Oncology, (Al Zahrani, Ghorbel, Mukhtar), King Salman Armed Forces Hospital, Tabuk; from the Department of Oncology, (Almajed, Abdelazim), Prince Sultan Military Medical City, Riyadh; from the Department of Oncology, (Hasan), Al Hada Armed Forces Hospital, Taif; and from the Department of Oncology, (Al Harbi, Ali Bajouda), King Fahad Armed Forces Hospital, Jeddah, Kingdom of Saudi Arabia.
Hoda M AbdelazimFrom the Department of Oncology, (Al Zahrani, Ghorbel, Mukhtar), King Salman Armed Forces Hospital, Tabuk; from the Department of Oncology, (Almajed, Abdelazim), Prince Sultan Military Medical City, Riyadh; from the Department of Oncology, (Hasan), Al Hada Armed Forces Hospital, Taif; and from the Department of Oncology, (Al Harbi, Ali Bajouda), King Fahad Armed Forces Hospital, Jeddah, Kingdom of Saudi Arabia.
Muhammad N HasanFrom the Department of Oncology, (Al Zahrani, Ghorbel, Mukhtar), King Salman Armed Forces Hospital, Tabuk; from the Department of Oncology, (Almajed, Abdelazim), Prince Sultan Military Medical City, Riyadh; from the Department of Oncology, (Hasan), Al Hada Armed Forces Hospital, Taif; and from the Department of Oncology, (Al Harbi, Ali Bajouda), King Fahad Armed Forces Hospital, Jeddah, Kingdom of Saudi Arabia.
Ahmad MostafaFrom the Department of Oncology, (Al Zahrani, Ghorbel, Mukhtar), King Salman Armed Forces Hospital, Tabuk; from the Department of Oncology, (Almajed, Abdelazim), Prince Sultan Military Medical City, Riyadh; from the Department of Oncology, (Hasan), Al Hada Armed Forces Hospital, Taif; and from the Department of Oncology, (Al Harbi, Ali Bajouda), King Fahad Armed Forces Hospital, Jeddah, Kingdom of Saudi Arabia.
Aisha A Al HarbiFrom the Department of Oncology, (Al Zahrani, Ghorbel, Mukhtar), King Salman Armed Forces Hospital, Tabuk; from the Department of Oncology, (Almajed, Abdelazim), Prince Sultan Military Medical City, Riyadh; from the Department of Oncology, (Hasan), Al Hada Armed Forces Hospital, Taif; and from the Department of Oncology, (Al Harbi, Ali Bajouda), King Fahad Armed Forces Hospital, Jeddah, Kingdom of Saudi Arabia.
Ali BajoudaFrom the Department of Oncology, (Al Zahrani, Ghorbel, Mukhtar), King Salman Armed Forces Hospital, Tabuk; from the Department of Oncology, (Almajed, Abdelazim), Prince Sultan Military Medical City, Riyadh; from the Department of Oncology, (Hasan), Al Hada Armed Forces Hospital, Taif; and from the Department of Oncology, (Al Harbi, Ali Bajouda), King Fahad Armed Forces Hospital, Jeddah, Kingdom of Saudi Arabia.
Riyadh Armed Forces Hospital · SAArmed Forces Hospital · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo evaluate the impact of COVID-19 on cancer management in Saudi Arabia's military hospitals.

methodsThis multi-centric, retrospective study compared cancer patients diagnosed from February-July 2019 and 2020, focusing on the time duration for acceptance and time for oncologic treatment initiation. Eligibility and referral status were recorded. Clinical data of COVID-19-positive cancer patients were collected and evaluated their outcomes and survival.

resultsData of 1574 cancer patients (mean age, 57.1 years) were collected. Mean time for acceptance was 7.3 days in 2019 and 8 days in 2020, with no statistically significant difference. Mean time for oncology treatment initiation was 38.4 days in 2019 and 44.3 days in 2020, with no statistically significant difference. The number of new cancer patients decreased in 2020 but increased in peripheral hospitals. It decreased in Riyadh and Jeddah hospitals. Concerning referral status, a statistically significant modification was recorded only in Riyadh and Tabuk hospitals. No significant changes observed in time duration for acceptance of new patients and oncology treatment initiation from 2019-2020. A total of 76 COVID-19-positive cancer patients recorded; 72% were symptomatic, 73.6% recovered, 22.3% died due to COVID-19 complications, and 8% died due to cancer; cancer progressed in 7 patients.

conclusionCOVID-19 did not affect oncology service in Saudi Arabia's military hospitals. New cancer cases reduced during the pandemic. Cancer patients are at increased risk for COVID-19 complications, including death.

Indexed as

COVID-19NeoplasmsHospitals, MilitaryHumansMiddle AgedRetrospective StudiesSARS-CoV-2Saudi ArabiaUnited Statescancer managementCOVID-19military hospitalsoncologypandemic

Identifiers

PMID34853131
PMCPMC9149751
OpenAlexW3216782464

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.